celebrating 20 years at axogen
This year, Axogen celebrates its 20th anniversary of revolutionizing the science of nerve repair and helping to improve quality of life and restore feeling and functionality to patients with damaged peripheral nerves.
Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Axogen’s comprehensive portfolio of products continues to help patients regain the ability to kiss, smile, hug, walk, eat, touch, run, feel—some of the many things healthy peripheral nerves allow us to do.
We are celebrating our role as the leading company specifically dedicated to improving quality of life for patients suffering from peripheral nerve injuries and our 20 years of unwavering focus on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair.
our commitment to our mission
Our dedication to improved patient outcomes has been at the core of our business since our founding in 2002, and today it fuels Axogen’s innovative product portfolio, physician education initiatives, clinical research, and patient awareness campaigns.
We have continued to expand applications and increase adoption of our platform for nerve repair, simultaneously growing our business and the market in pursuit of our mission.
Read Patient stories
our clinical innovation
Axogen is a company built on science and innovation – they are common threads woven throughout our 20-year history and across our company. As we continue to grow, our corporate reputation is anchored by innovation. Learn about how our clinical studies are advancing peripheral nerve science.learn more
Check out some of our key milestones and proudest moments from the past 20 years:
Axogen is founded
Axogen licensed technology from the University of Florida and the University of Texas Austin
Axogen receives first VC funding, opens dedicated labs for peripheral nerve research at the Biotech Development Incubator of UF, and creates Axogenic values
First implant of Avance® Nerve Graft at Mayo Clinic
RANGER® registry is initiated
Axoguard Nerve Protector® and Axoguard Nerve Connector® are launched
U.S. FDA grants enforcement discretion letter for Avance
Axogen becomes public company (AXGN)
Axogen expands into oral & maxillofacial (OMF) market and begins the MATCH® study
Burleson, TX distribution center opens
First implant made in RECONSM study and Dayton, OH processing center opens
Axogen expands into breast neurotization with Resensation®, launches patient website, and receives RMAT designation for Avance® Nerve Graft
Axogen achieves $100+ million in annual revenue, expands sales team to over 100 reps, and 100th peer-reviewed clinical paper featuring Axogen technologies is published
Axogen expands into the surgical treatment of pain, reaches RECON study enrollment, publishes key RANGER and MATCH study data, and opens Tampa office and research labs
REPOSE® study completes pilot phase
Axogen announces positive topline results from Phase 3 RECON study for Avance, publishes REPOSE pilot study results, and initiates REPOSE-XLSM study